Immunological response induced by abagovomab as a maintenance therapy in patients with epithelial ovarian cancer: relationship with survival—a substudy of the MIMOSA trial

Cancer Immunology, Immunotherapy

Volumn 63, Issue 10, 2014, Pages 1037-1045

  Buzzonetti, Alexia ^a   Fossati, Marco ^a   Catzola, Valentina ^a   Scambia, Giovanni ^a   Fattorossi, Andrea ^a   Battaglia, Alessandra ^a  

^a CATHOLIC UNIVERSITY   (Italy)

Author keywords

Ab3; CA125 specific cytotoxic T lymphocytes; HAMA; MIMOSA trial; Ovarian cancer vaccine

Indexed keywords

ABAGOVOMAB; CA 125 ANTIGEN; EPITOPE; MEMBRANE PROTEIN; MONOCLONAL ANTIBODY; MUC16 PROTEIN, HUMAN;

CLINICAL TRIAL; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; DISEASE FREE SURVIVAL; DOUBLE BLIND PROCEDURE; FEMALE; HUMAN; IMMUNOLOGY; IMMUNOTHERAPY; MULTICENTER STUDY; NEOPLASMS, GLANDULAR AND EPITHELIAL; OVARIAN NEOPLASMS; RANDOMIZED CONTROLLED TRIAL; SURVIVAL; TREATMENT OUTCOME;

ANTIBODIES, MONOCLONAL; CA-125 ANTIGEN; DISEASE-FREE SURVIVAL; DOUBLE-BLIND METHOD; EPITOPES, T-LYMPHOCYTE; FEMALE; HUMANS; IMMUNOTHERAPY; MEMBRANE PROTEINS; NEOPLASMS, GLANDULAR AND EPITHELIAL; OVARIAN NEOPLASMS; SURVIVAL ANALYSIS; T-LYMPHOCYTES, CYTOTOXIC; TREATMENT OUTCOME;

EID: 84928585927     PISSN: 03407004     EISSN: 14320851     Source Type: Journal    
DOI: 10.1007/s00262-014-1569-0     Document Type: Article

References (22)

1. Gupta D, Lis CG (2009) Role of CA125 in predicting ovarian cancer survival—a review of the epidemiological literature. J Ovarian Res 2:13. doi:10.1186/1757-2215-2-13
2. Legge F, Paglia A, D’Asta M, Fuoco G, Scambia G, Ferrandina G (2011) Phase II study of the combination carboplatin plus celecoxib in heavily pre-treated recurrent ovarian cancer patients. BMC Cancer 11:214. doi:10.1186/1471-2407-11-214
3. Cannistra SA (2004) Cancer of the ovary. N Engl J Med 351:2519–2529
4. Ziebarth AJ, Landen CN, Alvarez RD (2012) Molecular/genetic therapies in ovarian cancer: future opportunities and challenges. Clin Obstet Gynecol 55:156–172
5. Miyake TM, Sood AK, Coleman RL (2013) Contemporary use of Bevacizumab in ovarian cancer. Exp Opin Biol Ther 13:283–294
6. Liu JF, Konstantinopoulos PA, Matulonis UA (2014) PARP inhibitors in ovarian cancer: Current status and future promise. Gynecol Oncol. doi:10.1016/j.ygyno.2014.02.039
7. Zhang L, Conejo-Garcia JR, Katsaros D, Gimotty PA, Massobrio M, Regnani G, Makrigiannakis A, Gray H, Schlienger K, Liebman MN, Rubin SC, Coukos G (2003) Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer. N Engl J Med 348:203–213
8. Berek JS, Taylor PT, Gordon A, Cunningham MJ, Finkler N, Orr J Jr, Rivkin S, Schultes BC, Whiteside TL, Nicodemus CF (2004) Randomized, placebo-controlled study of oregovomab for consolidation of clinical remission in patients with advanced ovarian cancer. J Clin Oncol 22:3507–3516
9. Baum RP, Noujaim AA, Nanci A, Moebus V, Hertel A, Niesen A, Donnerstag B, Sykes T, Boniface G, Hör G (1993) Clinical course of ovarian cancer patients under repeated stimulation of HAMA using MAb OC125 and B43.13. Hybridoma 12:583–589
10. Möbus VJ, Baum RP, Bolle M, Kreienberg R, Noujaim AA, Schultes BC, Nicodemus CF (2003) Immune responses to murine monoclonal antibody-B43.13 correlate with prolonged survival of women with recurrent ovarian cancer. Am J Obstet Gynecol 189:28–36
11. Gordon AN, Schultes BC, Gallion H, Edwards R, Whiteside TL, Cermak JM, Nicodemus CF (2004) CA125- and tumor-specific T-cell responses correlate with prolonged survival in oregovomab-treated recurrent ovarian cancer patients. Gynecol Oncol 94:340–351
12. Braly P, Nicodemus CF, Chu C, Collins Y, Edwards R, Gordon A, McGuire W, Schoonmaker C, Whiteside T, Smith LM, Method M (2009) The Immune adjuvant properties of front-line carboplatin-paclitaxel: a randomized phase 2 study of alternative schedules of intravenous oregovomab chemoimmunotherapy in advanced ovarian cancer. J Immunother 32:54–65
13. Jerne NK (1974) Towards a network theory of the immune system. Ann immunol 125C(1–2):373–389
14. Gómez RE, Ardigo ML (2012) Anti-idiotype antibodies in cancer treatment: the pharmaceutical industry perspective. Front Oncol 2:147. doi:10.3389/fonc.2012.00147
15. Schlebusch H, Wagner U, Grünn U, Schultes BA (1995) Monoclonal antiidiotypic antibody ACA 125 mimicking the tumor-associated antigen CA 125 for immunotherapy of ovarian cancer. Hybridoma 14:167–174
16. Reinartz S, Köhler S, Schlebusch H, Krista K, Giffels P, Renke K, Huober J, Möbus V, Kreienberg R, DuBois A, Sabbatini P, Wagner U (2004) Vaccination of patients with advanced ovarian carcinoma with the anti-idiotype ACA125: immunological response and survival (phase Ib/II). Clin Cancer Res 10:1580–1587
17. Pfisterer J, du Bois A, Sehouli J, Loibl S, Reinartz S, Reuss A, Canzler U, Belau A, Jackisch C, Kimmig R, Wollschlaeger K, Heilmann V, Hilpert F (2006) The anti-idiotypic antibody abagovomab in patients with recurrent ovarian cancer. A phase I trial of the AGO-OVAR. Ann Oncol 17:1568–1577
18. Sabbatini P, Dupont J, Aghajanian C, Derosa F, Poynor E, Anderson S, Hensley M, Livingston P, Iasonos A, Spriggs D, McGuire W, Reinartz S, Schneider S, Grande C, Lele S, Rodabaugh K, Kepner J, Ferrone S, Odunsi K (2006) Phase I study of abagovomab in patients with epithelial ovarian, fallopian tube, or primary peritoneal cancer. Clin Cancer Res 12:5503–5510
19. Sabbatini P, Harter P, Scambia G, Sehouli J, Meier W, Wimberger P, Baumann KH, Kurzeder C, Schmalfeldt B, Cibula D, Bidzinski M, Casado A, Martoni A, Colombo N, Holloway RW, Selvaggi L, Li A, del Campo J, Cwiertka K, Pinter T, Vermorken JB, Pujade-Lauraine E, Scartoni S, Bertolotti M, Simonelli C, Capriati A, Maggi CA, Berek JS, Pfisterer J (2013) Abagovomab as maintenance therapy in patients with epithelial ovarian cancer: a Phase III trial of the AGO OVAR, COGI, GINECO, and GEICO—the MIMOSA study. J Clin Oncol 31:1554–1561
20. Waldrop SL, Davis KA, Maino VC, Picker LJ (1998) Normal human CD4+ memory T cells display broad heterogeneity in their activation threshold for cytokine synthesis. J Immunol 161:5284–5295
21. Fattorossi A, Battaglia A, Ferrandina G, Coronetta F, Legge F, Salutari V, Scambia G (2004) Neoadjuvant therapy changes the lymphocyte composition of tumor-draining lymph nodes in cervical carcinoma. Cancer 100:1418–1428
22. Campoli M, Ferris R, Ferrone S, Wang X (2010) Immunotherapy of malignant disease with tumor antigen (TA)- specific monoclonal antibodies: does its therapeutic efficacy require cooperation with TA-specific CTL? Clin Cancer Res 16:11–20